BridgeBio Pharma, Inc. expected to post a loss of 59 cents a share - Earnings Preview
BridgeBio Pharma, Inc. BBIO.O is expected to show a rise in quarterly revenue when it reports results on October 29 for the period ending September 30 2026
The Palo Alto California-based company is expected to report a 136.5% increase in revenue to $285.497 million from $120.7 million a year ago, according to the mean estimate from 18 analysts, based on LSEG data.
LSEG's mean analyst estimate for BridgeBio Pharma, Inc. is for a loss of 59 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had fallen by about 0.9% in the last three months.
Wall Street's median 12-month price target for BridgeBio Pharma, Inc. is $108.50, about 59.2% above its last closing price of $68.15
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2026 | -0.62 | -0.58 | -0.78 | Missed | -33.7 |
Mar. 31 2026 | -0.67 | -0.68 | -0.84 | Missed | -23.8 |
Dec. 31 2025 | -0.81 | -0.74 | -1.00 | Missed | -34.7 |
Sep. 30 2025 | -0.88 | -0.89 | -0.95 | Missed | -6.9 |
Jun. 30 2025 | -0.76 | -0.84 | -0.95 | Missed | -12.6 |
Mar. 31 2025 | -0.92 | -0.92 | -0.88 | Beat | 4.7 |
Dec. 31 2024 | -1.17 | -1.13 | -1.40 | Missed | -23.8 |
Sep. 30 2024 | -0.92 | -0.98 | -1.10 | Missed | -12.4 |
This summary was machine generated October 27 at 20:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)